# Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. is a company headquartered in Boulder, CO, United States.

## Company overview

- **Legal name:** Fresh Tracks Therapeutics, Inc.
- **Former names in filing history:** Brickell Biotech, Inc. (2019-09-03 to 2022-09-06); VICAL INC (1995-02-15 to 2019-08-30); VICAL, INC. (1994-02-11 to 1994-02-11)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Boulder, CO, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000819050

## About

Fresh Tracks Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000819050, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2024-03-15, it reported annual revenue of USD 8,006,000; net income of USD -5,694,000; total assets of USD 11,586,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $8.0M (USD 8,006,000)
- **Net income:** -$5.7M (USD -5,694,000)
- **Total assets:** $11.6M (USD 11,586,000)
- **Cash and equivalents:** $10.9M (USD 10,868,000)
- **Operating cash flow:** -$4.3M (USD -4,343,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $6.9M (USD 6,943,000)
- **Net income:** -$21.1M (USD -21,102,000)
- **Total assets:** $10.3M (USD 10,271,000)
- **Cash and equivalents:** $8.7M (USD 8,680,000)
- **Operating cash flow:** -$19.3M (USD -19,335,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $404,000 (USD 404,000)
- **Net income:** -$39.5M (USD -39,474,000)
- **Total assets:** $29.7M (USD 29,717,000)
- **Cash and equivalents:** $26.9M (USD 26,884,000)
- **Operating cash flow:** -$36.1M (USD -36,148,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $1.8M (USD 1,822,000)
- **Net income:** -$20.9M (USD -20,913,000)
- **Total assets:** $33.6M (USD 33,634,000)
- **Cash and equivalents:** $30.1M (USD 30,115,000)
- **Operating cash flow:** -$20.0M (USD -20,034,000)

## Recent SEC filings

- Form SC 13D — filed 2024-05-08 — SCHEDULE 13D
- Form 10-K — filed 2024-03-15 — period 2023-12-31 — 10-K
- Form 8-K — filed 2024-03-07 — period 2024-03-05 — 8-K
- Form 8-K — filed 2024-02-16 — period 2024-02-15 — 8-K
- Form DEF 14A — filed 2024-01-17 — period 2024-02-15 — DEF 14A
- Form 8-K — filed 2024-01-03 — period 2023-12-27 — 8-K
- Form 8-K — filed 2023-12-27 — period 2023-12-27 — 8-K
- Form 8-K — filed 2023-12-18 — period 2023-12-15 — 8-K
- Form 8-K — filed 2023-12-15 — period 2023-12-14 — 8-K
- Form 8-K — filed 2023-12-15 — period 2023-12-15 — 8-K
- Form 8-K — filed 2023-12-01 — period 2023-11-30 — 8-K
- Form SC 13G — filed 2023-11-28 — SCHEDULE 13G

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/fresh-tracks-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology